Results of Meeting
Released
Released
Announcement PDF
ASX/NASDAQ Announcement
12 February 2026
2026 Extraordinary General Meeting Results
In accordance with ASX Listing Rule 3.13.2 and Section 251AA of the Corporations Act 2001 Immuron
Limited (ASX: IMC; NASDAQ: IMRN or the Company) advises that the shareholders of the Company passed
all resolutions in the Notice of Meeting at the 2026 Extraordinary General Meeting held earlier today.
All resolutions put to the meeting were carried by way of a poll. All resolutions were carried. Details of the
resolutions and the proxies received in respect of each resolution are set out in the attached proxy
summary.
- - - END - - -
This release has been authorised by the Directors of Immuron Limited.
Further information
Steven Lydeamore
Chief Executive Officer
steve@immuron.com
About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on
developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious
diseases.
Immuron Platform Technology
Immuron’s proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-
immune bovine colostrum. Immuron has the capability of producing highly specific immunoglobulins to any
enteric pathogen and our products are orally active. Bovine IgG can withstand the acidic environment of the
stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine
IgG also possesses this unique ability to remain active in the human GI tract delivering its full benefits directly to
the bacteria found there. The underlying nature of Immuron’s platform technology enables the development of
medicines across a large range of infectious diseases. The platform can be used to block viruses or bacteria at
mucosal surfaces such as the Gastrointestinal tract and neutralize the toxins they produce.
For more information visit: https://www.immuron.com.au/ and https://www.travelan.com
Sign up to Immuron’s Investor Hub: Here
FORWARD-LOOKING STATEMENTS:
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include,
but are not limited to, any statements relating to our growth strategy and product development programs and
any other statements that are not historical facts. Forward-looking statements are based on management’s
current expectations and are subject to risks and uncertainties that could negatively affect our business,
operating results, financial condition, and stock value. Factors that could cause actual results to differ materially
from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform
under and maintain financing and strategic agreements and relationships; risks relating to the results of research
and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties
relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate
and retain key personnel; the early stage of products under development; our need for substantial additional
funds; government regulation; patent and intellectual property matters; competition; as well as other risks
described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates
or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any
changes in events, conditions, or circumstances on which any such statement is based, except as required by law.
The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.
Resolution
Result
If s250U
applies
Resolution
Resolution
Type
For Against
Proxy's
Discretion
Abstain For Against Abstain*
Carried /
Not Carried
12,210,847 7,942,172 1,226,929 53,800 14,090,685 7,942,172 53,800
57.11% 37.15% 5.74% 63.95% 36.05%
12,210,847 7,942,172 1,226,929 53,800 14,090,685 7,942,172 53,800
57.11% 37.15% 5.74% 63.95% 36.05%
* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.
1. Ratification of prior
issue of shares – Listing
Rule 7.1
Ordinary Carried NA
2. Ratification of prior
issue of shares – Listing
Rule 7.1A
Ordinary Carried NA
Immuron Limited
General Meeting
Thursday, 12 February 2026
Results of Meeting
Resolution details
Instructions given to validly appointed proxies
(as at proxy close)
Number of votes cast on the poll
(where applicable)
Share your feedback
Discover